DDInter904 DDInter1628
An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Idarubicin {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Idarubicin {u} (Compound) downregulates {v} (Gene) PLK4
PLK4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Idarubicin {u} (Compound) upregulates {v} (Gene) PHKG2
PHKG2 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Idarubicin {u} (Compound) downregulates {v} (Gene) FOXJ3
FOXJ3 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Idarubicin {u} (Compound) upregulates {v} (Gene) KIAA0753
KIAA0753 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Idarubicin {u} (Compound) downregulates {v} (Gene) KIAA0907
KIAA0907 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Idarubicin {u} (Compound) upregulates {v} (Gene) SLC25A4
SLC25A4 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Idarubicin {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Idarubicin {u} (Compound) downregulates {v} (Gene) DYRK1A
DYRK1A {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Idarubicin {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is associated with {v} (Gene) JAK1
JAK1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Idarubicin (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Idarubicin (Compound) downregulates PLK4 (Gene) and PLK4 (Gene) is bound by Ruxolitinib (Compound)
Idarubicin (Compound) upregulates PHKG2 (Gene) and PHKG2 (Gene) is bound by Ruxolitinib (Compound)
Idarubicin (Compound) downregulates FOXJ3 (Gene) and FOXJ3 (Gene) is upregulated by Ruxolitinib (Compound)
Idarubicin (Compound) upregulates KIAA0753 (Gene) and KIAA0753 (Gene) is upregulated by Ruxolitinib (Compound)
Idarubicin (Compound) downregulates KIAA0907 (Gene) and KIAA0907 (Gene) is downregulated by Ruxolitinib (Compound)
Idarubicin (Compound) upregulates SLC25A4 (Gene) and SLC25A4 (Gene) is downregulated by Ruxolitinib (Compound)
Idarubicin (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Ruxolitinib (Compound)
Idarubicin (Compound) downregulates DYRK1A (Gene) and DYRK1A (Gene) is bound by Ruxolitinib (Compound) and DYRK1A (Gene) is upregulated by Ruxolitinib (Compound)
Idarubicin (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is associated with JAK1 (Gene) and JAK1 (Gene) is bound by Ruxolitinib (Compound)